摘要
目的对3种临床常用治疗中重度原发性高血压方案[硝苯地平缓释片、缬沙坦片;缬沙坦氢氯噻嗪（复方制剂）]进行药物经济学评价。方法选择94例中重度原发性高血压病患者,随机分成3组。硝苯地平缓释片组：单用硝苯地平缓释片30mg,每天1次;缬沙坦片组：缬沙坦片80mg,每天1次;缬沙坦氢氯噻嗪（复方制剂）合用组：1粒,每天1次;3组疗程均为12周,观察3组的疗效并进行成本效果分析法和敏感度分析。结果 3组治疗方案对中重度原发性高血压的治疗效果差异无显著性,成本差异有显著性。结论缬沙坦片治疗中重度原发性高血压成本效果比最佳,值得临床推广。
Objective To evaluate three pharmacotherapeutic regimens for moderate and severe primary hypertension. Methods 94 patients with moderate and severe hypertension were randomized into three groups,i.e.,the group treated with extended release nifedipine tablets,the group treated with valsartan tablets,and the group treated with valsartan and hydrochlorothiazide tablets. The first group only used extended release nifedipine tablets at 30 mg once daily,the second group used valsartan tablets at 80 mg once daily,and the third group used valsartan and hydrochlorothiazide tablets once daily. The course of treatment for all three groups lasted for 12 weeks. Results There was no significant difference in the thee groups of the patients with moderate and severe hypertension treated with different pharmacotherapeutic regimens,however,the costs of different pharmacotherapeutic regimens showed significant difference. Conclusion Valsartan showed the best cost-effectiveness among the three pharmacotherapeutic regimens.
出处
《广东药学院学报》
CAS
2010年第4期409-411,共3页
Academic Journal of Guangdong College of Pharmacy
基金
2007年东莞市科技计划(2007105150074)
